CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 16, 2020—Qiagen launched its novel Therascreen BRAF V600E RGQ PCR Kit following FDA approval of the kit as a companion diagnostic to the BRAF inhibitor Braftovi (encorafenib). Detection of the V600E mutation using the Therascreen BRAF V600E assays will help identify patients eligible for treatment with the newly FDA-approved combination of Braftovi and cetuximab in adults with previously treated metastatic colorectal cancer with a BRAF V600E mutation. The Therascreen BRAF V600E kit runs on the company’s Rotor-Gene Q MDx.